Benevolentai
BenevolentAI is a biotechnology company that utilizes AI-driven drug discovery to develop innovative drug candidates with enhanced chances of clinical success, supported by a robust pipeline of over 20 programs and strategic partnerships with pharmaceutical firms.
Benevolentai Overview
Benevolentai Funding Rounds
Round | Date | Amount Raised | Valuation | Investors | Sources |
---|---|---|---|---|---|
Reverse Merger | 4/22/2022 | ||||
PE Growth/Expansion | 9/17/2019 | ||||
PE Growth/Expansion | 4/19/2018 | ||||
PE Growth/Expansion | 8/1/2015 | ||||
PE Growth/Expansion | 10/17/2014 |
Benevolentai 409a Valuations
Date | Price per share | Est. Valuation | Filling |
---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Benevolentai Filings
Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Latest Benevolentai News
Chutes & Ladders—Less than a year in, BenevolentAI CEO is out
Fierce BiotechOctober 18, 2024
Co-founders Mulvaney, Brennan return to BenevolentAI as CEO Moeller departs
BioCenturyOctober 18, 2024
BenevolentAI CEO is out after less than a year on the job
Endpoints NewsOctober 17, 2024
BenevolentAI welcomes back founder Kenneth Mulvany as executive chairman
Proactive Investors UKOctober 17, 2024
BenevolentAI welcomes back founder Kenneth Mulvany as executive chairman
Proactive financial newsOctober 17, 2024
BenevolentAI welcomes back founder Kenneth Mulvany as executive chairman
Proactive Investors USAOctober 17, 2024
BenevolentAI Appoints Kenneth Mulvany as Executive Chairman
Business WireOctober 17, 2024
BenevolentAI to present R2E system at BioTechX Europe event in Basel
Proactive financial newsOctober 10, 2024